Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Mallinckrodt PLC MCKPF

Mallinckrodt plc develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies. The Company operates in two reportable segments: Specialty Brands and Specialty Generics. The Specialty Brands includes specialty pharmaceutical brands. The Specialty Generics includes niche specialty generic drugs and active pharmaceutical ingredients. Its Specialty Generics segment is focused on providing its customers with specialty generic drugs and active pharmaceutical ingredients (APIs). The Company focuses on various therapeutic areas, such as autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics, cultured skin substitutes and gastrointestinal products. Its product portfolio includes Acthar Gel, INOmax, Therakos photopheresis, StrataGraft, Terlivaz, and Amitiza.


OTCPK:MCKPF - Post by User

Bullboard Posts
Post by Schaffhausenon Aug 24, 2013 10:24am
578 Views
Post# 21695021

Mallinckrodt Senior VP Leaving the Company - Tom Berry, Senior VP, Product Supply

Mallinckrodt Senior VP Leaving the Company - Tom Berry, Senior VP, Product SupplyMNK Senior VP of Product Supply, Tom Berry, departing MNK as of Sept.30.  This announcement was filed by MNK in an 8-K form with the SEC on Aug.23.
Bullboard Posts